Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T13:40:56.668Z.
Consensus retrieved: 2026-10-06T09:00:39.081Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T13:40:56.668Z.
Quote observation: 2026-10-06T13:40:04.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 6996458552ac01ead3128d6556e83e4bb1963b7ff03457c6e44cd5b005f304fe
Forward PE Ratio (N/A) = Dated Quote Price ($61.50) / Consensus Forward EPS ($-4.80)
FORWARD PE RATIO
N/A
Arrowhead Pharmaceuticals, Inc.
Market Cap
$8.66B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Arrowhead Pharmaceuticals, Inc. (ARWR) | $8.66B | N/A |
| Axsome Therapeutics, Inc. (AXSM)vs › | $8.98B | N/A |
| Caris Life Sciences, Inc. (CAI)vs › | $9.08B | 276.74 |
| Oscar Health, Inc. (OSCR)vs › | $8.43B | 17.03 |
| Kymera Therapeutics, Inc. (KYMR)vs › | $9.13B | N/A |
| Insulet Corp. (PODD)vs › | $9.39B | 20.85 |
| Bruker Corporation (BRKRP)vs › | $9.57B | 224.71 |
| Henry Schein, Inc. (HSIC)vs › | $9.76B | 15.91 |
| Hinge Health, Inc. (HNGE)vs › | $7.72B | 43.03 |
| Cytokinetics, Incorporated (CYTK)vs › | $7.71B | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2027-09-30
At the dated quote price of $61.50, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2027-09-30 | $-4.80 | $-6.68 – $-2.54 | 12 | n/m |
| 2028-09-30 | $-2.95 | $-6.17 – $0.17 | 7 | n/m |
| 2029-09-30 | $-0.74 | $-2.06 – $1.00 | 5 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
